Biased Ligands. Better Drugs.

TRV130 - Mu Opioid Biased Ligand for Acute Pain

Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
OwnershipCollaborator
TRV027 Angiotensin II type 1 receptor Acute Heart Failure intravenous Actavis
TRV130 Mu-opioid
receptor
Postoperative
Pain
intravenous Trevena Logo
TRV734 Mu-opioid
receptor
Moderate to
Severe Pain
oral Trevena Logo
Delta
Opioid
Delta-opioid
receptor
CNS   Actavis

TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate to severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute postoperative pain.

View TRV130 Publications

Copyright © Trevena, Inc.